Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline.

Nettiksimmons J, Harvey D, Brewer J, Carmichael O, DeCarli C, Jack CR Jr, Petersen R, Shaw LM, Trojanowski JQ, Weiner MW, Beckett L; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2010 Aug;31(8):1419-28. doi: 10.1016/j.neurobiolaging.2010.04.025. Epub 2010 Jun 9.

2.

MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.

Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2009 Jul 28;73(4):294-301. doi: 10.1212/WNL.0b013e3181af79fb.

3.

Biomarkers for predicting cognitive decline in those with normal cognition.

Steenland K, Zhao L, Goldstein F, Cellar J, Lah J.

J Alzheimers Dis. 2014;40(3):587-94. doi: 10.3233/JAD-2014-131343.

4.

MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations.

Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2009 Jul 28;73(4):287-93. doi: 10.1212/WNL.0b013e3181af79e5.

5.

Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification.

Davatzikos C, Bhatt P, Shaw LM, Batmanghelich KN, Trojanowski JQ.

Neurobiol Aging. 2011 Dec;32(12):2322.e19-27. doi: 10.1016/j.neurobiolaging.2010.05.023. Epub 2010 Jul 1.

6.

Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.

Da X, Toledo JB, Zee J, Wolk DA, Xie SX, Ou Y, Shacklett A, Parmpi P, Shaw L, Trojanowski JQ, Davatzikos C; Alzheimer's Neuroimaging Initiative.

Neuroimage Clin. 2013 Nov 28;4:164-73. doi: 10.1016/j.nicl.2013.11.010. eCollection 2014.

7.

Regional cortical thinning and cerebrospinal biomarkers predict worsening daily functioning across the Alzheimer's disease spectrum.

Marshall GA, Lorius N, Locascio JJ, Hyman BT, Rentz DM, Johnson KA, Sperling RA.

J Alzheimers Dis. 2014;41(3):719-28. doi: 10.3233/JAD-132768.

8.

CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease.

Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, Brewer JB, Dale AM; Alzheimer's Disease Neuroimaging Initiative.

J Neurosci. 2010 Feb 10;30(6):2088-101. doi: 10.1523/JNEUROSCI.3785-09.2010.

9.

Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.

Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P, Goldberg TE; Alzheimer's Disease Neuroimaging Initiative.

Arch Gen Psychiatry. 2011 Sep;68(9):961-9. doi: 10.1001/archgenpsychiatry.2011.96.

PMID:
21893661
10.

Longitudinal change of biomarkers in cognitive decline.

Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2011 Oct;68(10):1257-66. doi: 10.1001/archneurol.2011.123. Epub 2011 Jun 13.

PMID:
21670386
11.

Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease.

Okonkwo OC, Alosco ML, Griffith HR, Mielke MM, Shaw LM, Trojanowski JQ, Tremont G; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2010 Jun;67(6):688-96. doi: 10.1001/archneurol.2010.118.

12.

Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers.

Shaffer JL, Petrella JR, Sheldon FC, Choudhury KR, Calhoun VD, Coleman RE, Doraiswamy PM; Alzheimer’s Disease Neuroimaging Initiative.

Radiology. 2013 Feb;266(2):583-91. doi: 10.1148/radiol.12120010. Epub 2012 Dec 11.

13.

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Ann Neurol. 2009 Apr;65(4):403-13. doi: 10.1002/ana.21610.

14.

Multimodal classification of Alzheimer's disease and mild cognitive impairment.

Zhang D, Wang Y, Zhou L, Yuan H, Shen D; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2011 Apr 1;55(3):856-67. doi: 10.1016/j.neuroimage.2011.01.008. Epub 2011 Jan 12.

15.

The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes.

Beckett LA, Harvey DJ, Gamst A, Donohue M, Kornak J, Zhang H, Kuo JH; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 May;6(3):257-64. doi: 10.1016/j.jalz.2010.03.002.

16.

Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease.

Llano DA, Laforet G, Devanarayan V; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimer Dis Assoc Disord. 2011 Jan-Mar;25(1):73-84. doi: 10.1097/WAD.0b013e3181f5b8d8.

PMID:
20847637
17.

ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.

Apostolova LG, Hwang KS, Kohannim O, Avila D, Elashoff D, Jack CR Jr, Shaw L, Trojanowski JQ, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2014 Jan 4;4:461-72. doi: 10.1016/j.nicl.2013.12.012. eCollection 2014.

18.

Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer's disease biomarker related cognitive decline?

Ye BS, Lee WW, Ham JH, Lee JJ, Lee PH, Sohn YH; Alzheimer's Disease Neuroimaging Initiative.

Eur J Neurol. 2016 May;23(5):948-57. doi: 10.1111/ene.12969. Epub 2016 Feb 24.

PMID:
26917248
19.

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Dement. 2012 Feb;8(1 Suppl):S1-68. doi: 10.1016/j.jalz.2011.09.172. Epub 2011 Nov 2. Review.

20.

Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment.

Lorenzi M, Donohue M, Paternicò D, Scarpazza C, Ostrowitzki S, Blin O, Irving E, Frisoni GB; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2010 Aug;31(8):1443-51, 1451.e1. doi: 10.1016/j.neurobiolaging.2010.04.036. Epub 2010 Jun 11.

PMID:
20541287

Supplemental Content

Support Center